A retrospective study evaluating efficacy and safety of ALK Tyrosine Kinase Inhibitors in elderly patients with Advanced ALK-Positive Non-Small Cell Lung Cancer.Real life study
Latest Information Update: 12 Apr 2019
At a glance
- Drugs Alectinib (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 12 Apr 2019 New trial record
- 05 Apr 2019 Results published in the Oncology Research and Treatment